uniQure Submits BLA for AMT-130 in Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM, September 2, 2026 uniQure N.V. announced the submission of a Biologics License Application (BLA) to...
MHRA
Advertisement
Tasman Therapeutics Advances R-107 with Osmind Partnership
San Francisco, California, August 12, 2026 Tasman Therapeutics announced a multi-year strategic partnership with Osmind to support the development...
Rhythm Pharmaceuticals Expands IMCIVREE Authorization in UK
Boston, Massachusetts, August 11, 2026 Rhythm Pharmaceuticals announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA)...
INmune Bio Reports Q2 2026 Results and Pipeline Progress
BOCA RATON, Fla., August 6, 2026 INmune Bio Inc. reported its second quarter 2026 financial results while highlighting significant...
INmune Bio Reaches Commercial CORDStrom Manufacturing Milestone
BOCA RATON, Fla. | July 20, 2026 INmune Bio Inc. announced the successful completion of a major commercial manufacturing...
Advertisements
Savara MOLBREEVI MAA Accepted by UK MHRA for PAP
Langhorne, Pennsylvania, USA, April 7, 2026 MHRA Acceptance Marks Key Regulatory Milestone In a significant advancement for rare disease...
OS Therapies Advances OST-HER2 Toward FDA Approval
NEW YORK, March 31, 2026 — OS Therapies, Inc a clinical-stage oncology company specializing in listeria-based cancer immunotherapies, has...
OS Therapies Advances OST-HER2 Toward Phase 3 Trial
New York, March 27, 2026 OS Therapies has achieved a significant regulatory milestone by securing meetings with multiple global...
Tangram Advances TGM-312 With Phase 1/2 CTA Submission
LONDON — November 26, 2025. Tangram Therapeutics has submitted a Clinical Trial Application (CTA) to the UK Medicines and...
OS Therapies Reports 75% Two-Year Survival in Osteosarcoma Immunotherapy Trial
New York, NY – October 10, 2025 – OS Therapies Inc. has announced statistically significant positive final results from...
Advertisement
